AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11914258 — intervention group
Group type: EXPERIMENTAL
Intervention: GSNO (4.4 mmol/kg per minute)
Number of subjects: 20
Study 11914258 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study 9616538 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms salmeterol hydroxynaphthoate
Number of subjects: 12
Study 9616538 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms oxitropium bromide
Number of subjects: 12
Study 9616538 — intervention group
Group type: COMPARATOR
Intervention: 400 micrograms oxitropium bromide
Number of subjects: 12
Study 7623477 — intervention group
Group type: EXPERIMENTAL
Intervention: Televised warnings in beer advertisements
Number of subjects: 75
Study 7623477 — intervention group
Group type: COMPARATOR
Intervention: Televised advertisements without warnings
Number of subjects: 75
Study 2793338 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 15
Study 2793338 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 15
Study 2793338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2793338 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift in treatment
Number of subjects: 15
Study 2793338 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation level shifts
Number of subjects: 15
Study 2793338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood modalities
Number of subjects: 15
Study 214288 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimuli
Number of subjects: 11
Study 214288 — intervention group
Group type: EXPERIMENTAL
Intervention: Light stimuli
Number of subjects: 11
Study 214288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimuli
Number of subjects: 11
Study 214288 — intervention group
Group type: COMPARATOR
Intervention: No stimulus
Number of subjects: 11
Study 30622095 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized avatar
Number of subjects: 317
Study 30622095 — intervention group
Group type: COMPARATOR
Intervention: Assigned avatar
Number of subjects: 317
Study 27965111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 82
Study 27965111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 25347021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) sampling
Number of subjects: 593
Study 25347021 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT sampling
Number of subjects: 593
Study 23997371 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 mg)
Number of subjects: 21
Study 23997371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23997371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined eszopiclone and placebo groups
Number of subjects: 21
Study 21993153 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief transdiagnostic internet treatment (Wellbeing Program)
Number of subjects: 32
Study 20186639 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention (specific walking plans every 6 weeks)
Number of subjects: 75
Study 20186639 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention
Number of subjects: 75
Study 20186639 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-monitoring daily pedometer step count)
Number of subjects: 75
Study 16751038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens opacities in one or both eyes
Number of subjects: 700
Study 16751038 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous cataract surgery included
Number of subjects: 700
Study 16751038 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) testing
Number of subjects: 700
Study 15553105 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine difumarate (2 mg b.i.d.)
Number of subjects: 130
Study 15553105 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (60 mg b.i.d.)
Number of subjects: 130
Study 11325074 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (benazepril at a dose of 2.5 mg daily)
Number of subjects: 65
Study 11325074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphabeta blocker (arotinolol at a dose of 20 mg daily)
Number of subjects: 65
Study 9389395 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy
Number of subjects: 624
Study 9389395 — intervention group
Group type: COMPARATOR
Intervention: Total gastrectomy
Number of subjects: 624
Study 7956637 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal urinary albumin excretion (UAE)
Number of subjects: 481
Study 7956637 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 481
Study 7956637 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline UAE
Number of subjects: 481
Study 3791141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with chemotherapy and intensive meningeal radiotherapy (vincristine, actinomycin D, cyclophosphamide, Adriamycin, 4000 to 5500 rad radiation therapy, intrathecal drugs)
Number of subjects: 163
Study 3791141 — intervention group
Group type: COMPARATOR
Intervention: Preintensive treatment with chemotherapy and nonintensive meningeal radiotherapy (vincristine, actinomycin D, 4000 to 5500 rad radiation therapy)
Number of subjects: 163
Study 3791141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (within group analysis)
Number of subjects: 163
Study 28737251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 67
Study 28737251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 27780796 — intervention group
Group type: EXPERIMENTAL
Intervention: isafe intervention (eHealth safety decision aid)
Number of subjects: 1003
Study 27780796 — intervention group
Group type: EXPERIMENTAL
Intervention: Online classified advertising
Number of subjects: 1003
Study 27780796 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends and family referral
Number of subjects: 1003
Study 27780796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout analysis
Number of subjects: 1003
Study 24022862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily for 7 days)
Number of subjects: 34
Study 23757053 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IGF‐II concentration at baseline
Number of subjects: 485
Study 23757053 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 SNPs from the IGF2 and H19 genes
Number of subjects: 485
Study 23757053 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs10770063 and rs3842767
Number of subjects: 485
Study 20733306 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg RSG XR
Number of subjects: 693
Study 20733306 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg RSG XR
Number of subjects: 693
Study 20733306 — intervention group
Group type: COMPARATOR
Intervention: 10 mg donepezil (control)
Number of subjects: 693
Study 20733306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 693
Study 19053918 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 40
Study 19053918 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD)
Number of subjects: 40
Study 15911536 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stabilisation of the spine
Number of subjects: 349
Study 15911536 — intervention group
Group type: COMPARATOR
Intervention: Intensive rehabilitation programme
Number of subjects: 349
Study 12135948 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced 3D magnetic resonance angiography (MRA)
Number of subjects: 32
Study 12135948 — intervention group
Group type: COMPARATOR
Intervention: X-ray angiography (control)
Number of subjects: 32
Study 10410527 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercises (strengthening exercises for abdominal, gluteal, and leg muscles, stretching of the back, hip, hamstrings, and calf muscles, walking in water, and swimming)
Number of subjects: 35
Study 10410527 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercises (frequency: once a week, twice a week, or 3 or more times a week)
Number of subjects: 35
Study 7772012 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 2.5 mg daily
Number of subjects: 32
Study 7772012 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 5 mg daily
Number of subjects: 32
Study 7772012 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 10 mg daily
Number of subjects: 32
Study 7772012 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 2.5 mg, 5 mg, or 10 mg daily
Number of subjects: 32
Study 7772012 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 5 mg and 10 mg
Number of subjects: 32
Study 2149046 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin as first-line treatment
Number of subjects: 76
Study 2149046 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin as second-line therapy
Number of subjects: 76
Study 2149046 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus amikacin (initial regimen)
Number of subjects: 76
Study 461042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence that correctly labeled and described the physical arrangement of the objects
Number of subjects: 70
Study 461042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence containing the correct labels but not the correct physical arrangement
Number of subjects: 70
Study 461042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence which did not contain the correct labels and incorrectly described the physical arrangement
Number of subjects: 70
Study 461042 — intervention group
Group type: COMPARATOR
Intervention: Control conditions providing correct labels
Number of subjects: 70
Study 461042 — intervention group
Group type: COMPARATOR
Intervention: Control conditions omitting presentation of verbal prompts
Number of subjects: 70
Study 31935774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for 4 months, consisting of awareness/stabilization, strength training, and power phases.
Number of subjects: 14
Study 31935774 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study 30072155 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 12 weeks (3-min intervals at 40% and 80% of VO2peak, n = 17)
Number of subjects: 34
Study 30072155 — intervention group
Group type: COMPARATOR
Intervention: General healthcare (GHC) for 12 weeks (n = 17)
Number of subjects: 34
Study 27989018 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 0.4% + propylene glycol 0.3% (PP) eye drops
Number of subjects: 60
Study 27989018 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpreserved trehalose 3% + hyaluronic acid 0.15% (TH) eye drops
Number of subjects: 60
Study 27989018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.2% (HA) eye drops
Number of subjects: 60
Study 26154675 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based content refresher and complex airway management simulation
Number of subjects: 2
Study 26154675 — intervention group
Group type: COMPARATOR
Intervention: Complex airway management simulation only
Number of subjects: 2
Study 23537687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (solifenacin plus tamsulosin OCAS)
Number of subjects: 937
Study 23537687 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin OCAS alone
Number of subjects: 937
Study 21570188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Number of subjects: 105
Study 21570188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbendazole (FBZ)
Number of subjects: 105
Study 21570188 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 105
Study 19274516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three disease-modifying anti-rheumatic drugs (DMARDs)
Number of subjects: 162
Study 19274516 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD
Number of subjects: 162
Study 19274516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three DMARDs
Number of subjects: 162
Study 16679098 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (160 subjects receiving treatment)
Number of subjects: 745
Study 16679098 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (short duration <3 years)
Number of subjects: 745
Study 16679098 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (long duration 3 to 9 years)
Number of subjects: 745
Study 16679098 — intervention group
Group type: COMPARATOR
Intervention: Non-receiving ACE inhibitors (rest of study population)
Number of subjects: 745
Study 15599144 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 80
Study 15599144 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 80
Study 15599144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel-PAP
Number of subjects: 80
Study 15599144 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP or Bilevel-PAP
Number of subjects: 80
Study 15599144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy, CPAP, Bilevel-PAP
Number of subjects: 80
Study 16161718 — intervention group
Group type: EXPERIMENTAL
Intervention: Double versus triple antiretroviral therapy
Number of subjects: 23
Study 11079534 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg/day) for 6 weeks
Number of subjects: 100
Study 11079534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11079534 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg/day)
Number of subjects: 100
Study 8822354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density (BMD) measurements at the spine
Number of subjects: 1857
Study 8822354 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior history of fracture
Number of subjects: 1857
Study 8822354 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of hip fracture (maternal grandmother)
Number of subjects: 1857
Study 8822354 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal status or having a hysterectomy
Number of subjects: 1857
Study 1446443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension band wiring (TBW)
Number of subjects: 41
Study 1446443 — intervention group
Group type: COMPARATOR
Intervention: Plate fixation (PF)
Number of subjects: 41
Study 2937224 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 127
Study 2937224 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and PTCA
Number of subjects: 127
Study 31257951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture barrier #1
Number of subjects: 20
Study 31257951 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 29967006 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation (tDCS)
Number of subjects: 81
Study 29967006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham controls)
Number of subjects: 81
Study 27686226 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mirabegron once daily
Number of subjects: 89
Study 27686226 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg imidafenacin twice daily
Number of subjects: 89
Study 24096138 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n=13)
Number of subjects: 22
Study 24096138 — intervention group
Group type: COMPARATOR
Intervention: Sedentary attention control (n=9)
Number of subjects: 22
Study 22853865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR 4 mg
Number of subjects: 20
Study 22853865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR 8 mg
Number of subjects: 20
Study 22853865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20164809 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (N3) - 2000 mg eicosapentaenoic acid and 400 mg docosahexaenoic acid
Number of subjects: 48
Study 20164809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-mineral complex (VM) - vitamins C (2000 mg), E (800 IU), A (3000 IU), selenium (200 microg)
Number of subjects: 48
Study 20164809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-mineral complex and n-3 fatty acid combination (VN3)
Number of subjects: 48
Study 20164809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 48
Study 17914135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D stores (18 ng/ml)
Number of subjects: 69
Study 17914135 — intervention group
Group type: COMPARATOR
Intervention: Adequate vitamin D stores (>34 ng/ml)
Number of subjects: 69
Study 16076305 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified D. pteronyssinus extract
Number of subjects: 55
Study 12120773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand excavation
Number of subjects: 36
Study 12120773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bur excavation
Number of subjects: 36
Study 12120773 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-abrasion
Number of subjects: 36
Study 12120773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sono-abrasion
Number of subjects: 36
Study 12120773 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation
Number of subjects: 36
Study 12120773 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical methods
Number of subjects: 36
Study 10204750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating Scale (RS)
Number of subjects: 281
Study 10204750 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG)
Number of subjects: 281
Study 7779152 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg aciclovir tablet (test formulation)
Number of subjects: 24
Study 7779152 — intervention group
Group type: COMPARATOR
Intervention: 200 mg aciclovir tablet (reference formulation)
Number of subjects: 24
Study 7779152 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg aciclovir tablet (test formulation)
Number of subjects: 24
Study 7779152 — intervention group
Group type: COMPARATOR
Intervention: 400 mg aciclovir tablet (reference formulation)
Number of subjects: 24
Study 2095841 — intervention group
Group type: EXPERIMENTAL
Intervention: Figurative version of the story 'Peaches the Cat'
Number of subjects: 14
Study 2095841 — intervention group
Group type: COMPARATOR
Intervention: Literal version of the story 'Peaches the Cat'
Number of subjects: 14
Study 30699446 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDT with anticoagulation
Number of subjects: 300
Study 29381110 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg
Number of subjects: 122
Study 29381110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 26368321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar puncture (LP)
Number of subjects: 3868
Study 26368321 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for PLPH
Number of subjects: 3868
Study 26368321 — intervention group
Group type: COMPARATOR
Intervention: Other factors
Number of subjects: 3868
Study 24524293 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood obesity prevention intervention with a parent modelling component
Number of subjects: 460
Study 21457411 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted transitional care intervention including home-based exercise strategies
Number of subjects: 128
Study 21457411 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 128
Study 20195151 — intervention group
Group type: EXPERIMENTAL
Intervention: SNB plus complete axillary dissection (AD arm)
Number of subjects: 516
Study 20195151 — intervention group
Group type: COMPARATOR
Intervention: SNB with axillary dissection only if the sentinel node contained metastases (SN arm)
Number of subjects: 516
Study 17881538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a 135 microg subcutaneously once per week
Number of subjects: 50
Study 17881538 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon alpha‐2a 3 million units subcutaneously thrice per week
Number of subjects: 50
Study 17881538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a
Number of subjects: 50
Study 17881538 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon alpha‐2a
Number of subjects: 50
Study 15633704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine executive function tasks (seven commonly used in clinical practice)
Number of subjects: 122
Study 15633704 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically driven analyses and SEM
Number of subjects: 122
Study 12658471 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide plus heparin
Number of subjects: 100
Study 12658471 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 100
Study 10338168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline plus hyaluronidase
Number of subjects: 83
Study 10338168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 83
Study 10338168 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl)
Number of subjects: 83
Study 10338168 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline plus hyaluronidase
Number of subjects: 83
Study 8901210 — intervention group
Group type: EXPERIMENTAL
Intervention: Music played at 70 dBA
Number of subjects: 90
Study 8901210 — intervention group
Group type: COMPARATOR
Intervention: Music played at 60 dBA
Number of subjects: 90
Study 8901210 — intervention group
Group type: COMPARATOR
Intervention: Music played at 80 dBA
Number of subjects: 90
Study 1959887 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg twice daily)
Number of subjects: 28
Study 1959887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6313561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemibody radiation (HBI)
Number of subjects: 65
Study 6313561 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 65
Study 6313561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemibody radiation (HBI) as a consolidating-maintenance agent
Number of subjects: 65